类似于自然产品的碎片解锁了酶标的新型化学类型――探索平原之外的选择
Anna Santura1, Janis Müller2, Madita Wolter2
1Johannes Gutenberg University Mainz, Department of Chemistry, Duesbergweg 10-14, Mainz 55128, Germany.
Journal of chemical information and modeling
|December 23, 2025
概括
研究人员使用新型碎片库选蛋白激酶A (PKA),确定了36个独特的碎片结合结构. 这些新型碎片为开发更有选择性和更成功的激酶抑制剂提供了潜力.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 药用化学 医学化学
背景情况:
- 蛋白激酶A (PKA) 是细胞信号传递中的关键酶.
- 开发选择性激酶抑制剂是药物发现的一个重大挑战.
- 需要新的化学支架来克服现有的激酶抑制剂的局限性.
研究的目的:
- 为了对与PKA.类似的自然产品碎片库进行晶体学选.
- 识别与PKA结合的新型碎片,包括那些准ATP位或全位的碎片.
- 描述已识别的碎片的结合方式和新性.
主要方法:
- 高性能浸泡系统用于PKA的结晶学选.
- 使用X射线晶体学选碎片库.
- 数据库挖掘,脚手架/化学型分析和化学信息学分析.
主要成果:
- 解决了36个碎片绑定的PKA结构,实现了41%的命中率.
- 已识别的碎片与ATP位点,外围位点或两者结合.
- 在阿斯基米尼布部位发现了一个结合碎片,另一个诱导着形状变化.
- 关于PKA相互作用的碎片及其天然产品父的确认新性.
- 有特征的碎片占据一个独特的化学空间,具有可取的类似药物的特性.
结论:
- 该研究发现了具有独特化学特性的新型PKA结合剂.
- 这些碎片代表了开发选择性和临床成功的激酶抑制剂的有希望的起点.
- 已识别的碎片结合到不同的部位,包括类似于阿西米尼布的全位,并诱导构造变化.
更多相关视频
06:26Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
5.4K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.8K
相关概念视频
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Structure-Activity Relationships and Drug Design
1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Amplifying Signals via Enzymatic Cascade
16.9K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
16.9K
